Theratechnologies establishes new at-the-market facility

Theratechnologies establishes new at-the-market facility
  TORONTO – Theratechnologies Inc. (TSX-TH, NASDAQ-THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has established an at-the-market equity program allowing Theratechnologies to issue and sell up to US $50 million common shares from treasury to the public at the Company’s sole discretion and at the prevailing market price. Sales of... Read More

CHAR announces California green hydrogen project

CHAR announces California green hydrogen project
TORONTO – CHAR Technologies Ltd. (TSXV: YES) announced a test project with Hitachi Zosen Inova (HZI) to develop a high-temperature pyrolysis to green hydrogen system at their existing San Luis Obispo anaerobic digestion facility in California. Under the definitive agreement with HZI’s SLO operating company, CHAR’s high-temperature pyrolysis system will process 18,000 tonnes per year of solid anaerobic digestate into... Read More

Awakn initiates program to develop ketamine-assisted therapies 

Awakn initiates program to develop ketamine-assisted therapies 
TORONTO – Awakn Life Sciences Corp. (NEO: AWKN), a biotechnology company with clinical operations developing and delivering psychedelic medicines to better treat addiction, announced that it will undertake a program of clinical research designed to demonstrate the effectiveness for ketamine-assisted psychotherapy against multiple addictions. Awakn estimates that between 15% and 20% of the global adult population, or between 840 million... Read More

Avicanna to supply Brazilian company with THC and CBD cannabis extracts

Avicanna to supply Brazilian company with THC and CBD cannabis extracts
TORONTO – Avicanna Inc. (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products reported that its majority owned Colombian subsidiary, Santa Marta Golden Hemp S.A.S., has executed a three year master supply agreement with a leading Brazilian pharmaceutical company to supply industrial volumes of high THC and high CBD... Read More

HaluGen partners with Maya Health on psychedelics test kit awareness

HaluGen partners with Maya Health on psychedelics test kit awareness
VANCOUVER – Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1), a biotechnology company focused on developing psychedelic medicines to treat addiction, has reported an agreement with Maya health PBC to help drive brand awareness of the Company’s Psychedelics Genetic Test kit, developed and commercialized by its wholly-owned subsidiary HaluGen Life Sciences Inc. Maya has developed a measurement-based care platform... Read More

Cybin selects anxiety disorder indications for psychedelic molecule 

Cybin selects anxiety disorder indications for psychedelic molecule 
  TORONTO  – Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, reported that it has selected social anxiety disorder and generalized anxiety disorder as the initial target indications for its proprietary psychedelic molecule CYB004. “People struggle with many different mental health challenges, but anxiety affects more people than any other,” said Dr. Alex Belser, Chief Clinical Officer.... Read More

MYND Life Sciences reports patent applications for depression and neuropsychiatric disorder drugs

MYND Life Sciences reports patent applications for depression and neuropsychiatric disorder drugs
  VANCOUVER – MYND Life Sciences Inc. (CSE: MYND) a drug research and development company focused on novel psychedelic drug development, diagnostic approaches and pharmaceuticals, reported it has filed additional provisional patents that utilize various psilocybin analogs to target clinical depression. Major Depressive Disorder is a common and severe illness that is estimated to affect approximately 264 million people globally.  MYND... Read More

Health Canada approves expansion of Mydecine’s cultivation for psilocybin mushrooms

Health Canada approves expansion of Mydecine’s cultivation for psilocybin mushrooms
DENVER – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, announced today that it has received approval from Health Canada to significantly expand its cultivation capabilities at Mydecine’s Canadian Current Good Manufacturing Practice (cGMP) facility at Applied Pharmaceutical Innovation (API).... Read More

$33 million announced to advance technology innovations in Alberta’s agriculture, agri-food, and forestry sectors

$33 million announced to advance technology innovations in Alberta’s agriculture, agri-food, and forestry sectors
  EDMONTON – Using drones to help reforest remote boreal environments. Reducing methane emissions from cattle by up to 90 per cent through feed additives. Leveraging artificial intelligence to optimize energy usage at a pulp mill. These are three of 17 technology innovations that will receive funding from the Government of Alberta through Emissions Reduction Alberta (ERA). Alberta’s Minister of... Read More

$25 million to support technology and business accelerators in Alberta

$25 million to support technology and business accelerators in Alberta
EDMONTON – Alberta Innovates is issuing a request for proposals for the development of business accelerators to vault Alberta’s promising start-ups and small and medium technology companies through scaleup and growth faster. Alberta has a scaleup gap. While half of all start-ups survive over five years, only 0.1 per cent of small firms become mid-sized, and only two per cent... Read More